Relay Therapeutics Inc (RLAY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 284.14 is considered Undervalued compared with the five-year average of -5.82. The fair price of Relay Therapeutics Inc (RLAY) is between 149.63 to 153.13 according to relative valuation method. Compared to the current price of 9.79 USD , Relay Therapeutics Inc By Undervalued By 93.46%.

Relative Value

Fair Zone

149.63-153.13

Current Price：9.79

93.46%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Relay Therapeutics Inc (RLAY) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Relay Therapeutics Inc (RLAY) has a current Price-to-Book (P/B) ratio of 2.32. Compared to its 3-year average P/B ratio of 1.35, the current P/B ratio is approximately 71.75% higher. Relative to its 5-year average P/B ratio of 2.27, the current P/B ratio is about 2.19% higher. Relay Therapeutics Inc (RLAY) has a Forward Free Cash Flow (FCF) yield of approximately -17.55%. Compared to its 3-year average FCF yield of -29.98%, the current FCF yield is approximately -41.45% lower. Relative to its 5-year average FCF yield of -19.65%, the current FCF yield is about -10.67% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RLAY competitors is 18568.78, providing a benchmark for relative valuation. Relay Therapeutics Inc Corp (RLAY.O) exhibits a P/S ratio of 284.14, which is -98.47% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RLAY increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RLAY in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RLAY currently overvalued or undervalued?

What is Relay Therapeutics Inc (RLAY) fair value?

RLAY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Relay Therapeutics Inc (RLAY) is between 149.63 to 153.13 according to relative valuation method.

How does RLAY's valuation metrics compare to the industry average?

The average P/S ratio for RLAY's competitors is 18568.78, providing a benchmark for relative valuation. Relay Therapeutics Inc Corp (RLAY) exhibits a P/S ratio of 284.14, which is -98.47% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Relay Therapeutics Inc (RLAY) as of Mar 03 2026?

As of Mar 03 2026, Relay Therapeutics Inc (RLAY) has a P/B ratio of 2.32. This indicates that the market values RLAY at 2.32 times its book value.

What is the current FCF Yield for Relay Therapeutics Inc (RLAY) as of Mar 03 2026?

As of Mar 03 2026, Relay Therapeutics Inc (RLAY) has a FCF Yield of -17.55%. This means that for every dollar of Relay Therapeutics Inc's market capitalization, the company generates -17.55 cents in free cash flow.

What is the current Forward P/E ratio for Relay Therapeutics Inc (RLAY) as of Mar 03 2026?

As of Mar 03 2026, Relay Therapeutics Inc (RLAY) has a Forward P/E ratio of -4.85. This means the market is willing to pay $-4.85 for every dollar of Relay Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Relay Therapeutics Inc (RLAY) as of Mar 03 2026?

As of Mar 03 2026, Relay Therapeutics Inc (RLAY) has a Forward P/S ratio of 284.14. This means the market is valuing RLAY at $284.14 for every dollar of expected revenue over the next 12 months.

RLAY Valuation